[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632574":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":29,"centralContacts":36,"locations":42,"responsibleParty":64,"collaborators":29,"id":68,"slug":29,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":29,"eligibilityCriteria":73,"healthyVolunteers":69,"sex":74,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":29,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":29,"overallStatus":44,"whyStopped":29,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Group T","EXPERIMENTAL","Patients included in this group will receive oral 150 mg theophylline anhydrous tablet (QuibronT\u002FSR, 300 mg dividose tablet, SmithKline Beecham Egypt L.L.C) every 12 hours.",[13],"Drug: Theophylline",{"label":15,"type":10,"description":16,"interventionNames":17},"Group S","Patients included in this group will receive oral 25 mg sumatriptan succinate tablet (Sumigran 25, 25 mg tablet, Sigma pharmaceutical industries, Egypt) every 12 hours.",[18],"Drug: Sumatriptan",{"label":20,"type":10,"description":21,"interventionNames":22},"Group G","Patients included in this group will receive 200 mg of gabapentin every 12 hours.",[23],"Drug: Gabapentin",[25,30,33],{"type":26,"name":27,"description":11,"armGroupLabels":28,"otherNames":29},"DRUG","Theophylline",[9],null,{"type":26,"name":31,"description":16,"armGroupLabels":32,"otherNames":29},"Sumatriptan",[15],{"type":26,"name":34,"description":21,"armGroupLabels":35,"otherNames":29},"Gabapentin",[20],[37],{"name":38,"role":39,"phone":40,"phoneExt":29,"email":41},"Asmaa R Eid, MSc","CONTACT","00201026382543","asmaaragabeid@gmail.com",[43],{"facility":5,"status":44,"city":45,"state":46,"zip":47,"country":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"RECRUITING","Tanta","El-Gharbia","31527","Egypt",{"type":50,"coordinates":51},"Point",[52,53],31.00192,30.78847,{"lat":53,"lon":52},[56,57,60,62],{"name":38,"role":39,"phone":40,"phoneExt":29,"email":41},{"name":58,"role":59,"phone":29,"phoneExt":29,"email":29},"Najat S Al Shamaa, MD","SUB_INVESTIGATOR",{"name":61,"role":59,"phone":29,"phoneExt":29,"email":29},"Jihan M Darwish, MD",{"name":63,"role":59,"phone":29,"phoneExt":29,"email":29},"Omnia A El Miseery, MD",{"type":65,"investigatorFullName":66,"investigatorTitle":67,"investigatorAffiliation":5,"oldNameTitle":29,"oldOrganization":29},"PRINCIPAL_INVESTIGATOR","Asmaa Ragab Mohamed","Assistant Lecturer of Anesthesiology, Surgical ICU and Pain Management, Tanta University, Tanta, Egypt.","100632574",false,"NCT07515456","Theophylline, Versus Sumatriptan and Gabapentin in The Treatment of Post-Dural Puncture Headache","A Comparison Between Safety and Efficacy of Theophylline, Versus Sumatriptan and Gabapentin in The Treatment of Post-Dural Puncture Headache: A Prospective Randomized Double Blinded Study","Inclusion Criteria:\n\n* Age from 21 to 50 years.\n* Both sexes.\n* American Society of Anesthesiologists (ASA) physical status ≤ II.\n* Patient's selection for this study will be based on clinical diagnosis suggesting post-dural puncture headache (PDPH) based on the International Headache Society criteria.\n* Patients with numeric rating scale (NRS) of ≥ 5.\n\nExclusion Criteria:\n\n* Pregnant women.\n* History of; chronic headache, cluster headache, migraine, convulsions, cerebrovascular accident, and previous neurological diseases.\n* Signs of meningismus.\n* Dysrhythmia.\n* Hypertension.\n* Ischemic heart disease.\n* Hyperthyroidism.\n* Peripheral vascular disease (ischemic colitis).\n* Liver or renal impairment.\n* Use of selective serotonin reuptake inhibitors.\n* Use of ergotamine derivatives in the past 24 hours.\n* Use of monoamine oxidase inhibitors in the last 2 weeks.\n* Use of any kind of opiates.\n* Allergy to the study medications and any contraindication of oral intake.","ALL","21 Years","50 Years",{"count":78,"type":79},75,"ESTIMATED","INTERVENTIONAL",[82],"NA","The aim of this study is to compare the safety and efficacy of theophylline, sumatriptan, and gabapentin in the treatment of post-dural puncture headache.",[27,31,34,85],"Post-Dural Puncture Headache","2026-03-31",{"date":88,"type":89},"2026-04-07","ACTUAL",{"date":91,"type":89},"2024-12-01",{"date":93,"type":79},"2026-11-01",{"name":5,"class":6},1]